In a move towards universal HIV care, the WHO and UNAIDS have implemented a plan to make antiretroviral therapy available to 3 million HIV/AIDS victims worldwide by the end of 2005.
The authors of a recent journal article believe that most doctors and clinical trial sponsors would not object to changes in regulations requiring doctors to disclose financial incentives to their patients.
Public health officials have a responsibility to alert the public to prospective dangers without unduly restricting individual freedom or adding to the stigmatization of certain illnesses.
Douglas E. Paull, MD, MS and Paul N. Uhlig, MD, MPA
Risk managers can help patient-subjects and clinician-researchers make informed novel device implantation decisions in the absence of preclinical trial data.
AMA J Ethics. 2020;22(11):E911-918. doi:
10.1001/amajethics.2020.911.
Medical ethicists have discussed the use of race classification in determining disease prevalence and the response of specific ethnic groups to different medications.
A case that explores the impact of financial incentives from insurance companies on the patient-physician relationship and whether or not they should be disclosed to a patient.